|
| Study | Sample design | Contrast dose | Renal status | CIN definition | Renal outcome | Preventive treatment used |
|
| Spinosa (2000) [112] | 35-Randomized | 0.29 mmol/kg (0.13–0.40 mmol/kg) Gadolinium; 51 mL (33–80 mL) nonionic contrast | Cr 1.5 mg/dL | 0.5 mg/dL increase in [Cr ] within 48 hours | 5 % (1/20) exposed to Gadolinium; 40% (6/15) exposed to nonionic contrast | Volume administration |
|
| Erley (2004) [113] | 21-Prospective, randomized study | mmol/kg Gadolinium; mmol/kg Iohexol | Cr 1.5 mg/dL or GFR 50 mL/min | 50% decrease in GFR | 50% (5/10) exposed to Gadolinium and 45% (5/11) exposed to Iohexol | Volume administration |
|
| Briguori (2006) [114] | 57-Retrospective study | mmol/kg Gadolinium based; mL Iodixanol | Cr 2 mg/dL or CrCL 40 mL/min | 0.5 mg/dL increase in [Cr ] within 48 hours or need for dialysis within 5 days | 28% (7/ 25) exposed to Gadolinium plus iodinated contrast and 6.5% (2/32) exposed to iodinated contrast alone | Normal saline plus N-acetylcysteine |
|
| Reed (2007) [115] | 169-Retrospective Study | mL Gadolinium (with Iodinated contrast dilution); mL iodinated contrast | CrCl 60 mL/min/1.73 , a serum Cr level 1.5 mL/dL, and not on hemodialysis. | 0.5 mg/dL increase in [Cr] within 5 days | 16% (14/90) of those exposed to diluted Gadolinium and 14% (11/79) of Iodinated contrast | N-acetylcysteine plus Volume administration |
|
| Kane [38] (2008) | 163-Retrospective Study | 3 comparative groups receiving mL Gadolinium; Gadolinium (with Iodinated contrast); Iodinated contrast | Cr 2 mg/dL | 0.5 mg/dL increase in [Cr] within 7 days | 5.3% (3/57) in Gadolinium only; 10.5% (4/38) in Gadolinium Iodinated Contrast; 20.6% (14/68) in Iodinated contrast alone | N-acetylcysteine plus Volume administration |
|
